The first ever meeting purpose-built for discussing the advancement of curative therapies for chronic HBV infection. 

Featuring an all-star speaker faculty from across industry, NGOs and academia, all dedicated to finding a curative therapy for Chronic HBV infection.  This is a unique opportunity to review the latest clinical investigations with novel and classic therapeutics including RNAi and immuno-therapies.

Here is just a snapshot of some of the speakers who are joining us:

Yuchun Nie, Senior scientist, Aligos Therapeutics
Gaston Picchio, Chief Development Officer, Arbutus Biopharma
William Delaney, Chief Scientific Officer, Virology, Assembly Biosciences (USA)
Stephane Daffis, Scientist II, Gilead Sciences
Patricia Mendez, Vice President – Clinical Development, Immunocore Ltd
Andrew Vaillant, Chief Scientific Officer, Replicor Inc.
Tom Evans, Chief Scientific Officer, Vaccitech
David Anderson, Chief Scientific Officer, VBI Vaccines Inc.

Don’t miss out on this opportunity to benchmark yourself against the competition, get a comprehensive update on how the field stands and network with peers from across the field at the inaugural Chronic Hepatitis B Drug Development Summit.  Find out more >> https://ter.li/haruyt